How to tell if a new marker improves prediction

European Urology

Volumn 60, Issue 2, 2011, Pages 226-228

  Nguyen, Carvell T ^a   Kattan, Michael W ^a  

^a LERNER RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

P2 PROSTATE SPECIFIC ANTIGEN; PROSTATE SPECIFIC ANTIGEN; UNCLASSIFIED DRUG;

ACCURACY; CLINICAL DECISION MAKING; CLINICAL PRACTICE; DISEASE MARKER; FOLLOW UP; HUMAN; PRIORITY JOURNAL; PROGNOSIS; PROSTATE CANCER; REVIEW;

HUMANS; MALE; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS;

EID: 79959549569     PISSN: 03022838     EISSN: 18737560     Source Type: Journal    
DOI: 10.1016/j.eururo.2011.04.029     Document Type: Editorial

References (5)

1. G. Guazzoni, L. Nava, and M. Lazzeri Prostate-specific antigen (PSA) isoform p2PSA significantly improves the prediction of prostate cancer at initial extended prostate biopsies in patients with total PSA between 2.0 and 10.0 ng/ml: results of a prospective study in a clinical setting Eur Urol 60 2011 214 222
2. R. Simon, and D.G. Altman Statistical aspects of prognostic factor studies in oncology Br J Cancer 69 1994 979 985 (Pubitemid 24161844)
3. M.W. Kattan Judging new markers by their ability to improve predictive accuracy J Natl Cancer Inst 95 2003 634 635 (Pubitemid 36603708)
4. E.W. Steyerberg, A.J. Vickers, and N.R. Cook Assessing the performance of prediction models: a framework for traditional and novel measures Epidemiology 21 2010 128 138
5. F.E. Harrell Jr., K.L. Lee, and D.B. Mark Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors Stat Med 15 1996 361 387 (Pubitemid 26072233)